LDL Receptor Polyclonal Antibody

LDL receptor (LDLR) is a cell surface glycoprotein that scavenges LDL from the blood and regulates plasma LDL levels.{13847} It is composed of an N-terminal signal sequence, a ligand-binding domain, an EGF precursor homology domain, an O-linked glycosylation domain, a transmembrane region, and a C-terminal cytoplasmic tail. LDLR is primarily expressed in the liver but is also found in the adrenal cortex.{13846} It mediates the endocytosis of LDL by binding to apolipoprotein E (ApoE) or ApoB on the LDL surface, thereby supplying cholesterol to cells.{13847} Protein levels of LDLR are decreased in HepG2 cells expressing proprotein convertase subtilisin kexin 9 (PCSK9).{13135} Knockout of Ldlr increases plasma levels of cholesterol and triglycerides and induces the formation of atherosclerotic lesions in mice.{9904} Mutations in LDLR are associated with familial hypercholesterolemia.{13160} Cayman's LDL Receptor Polyclonal Antibody can be used for immunocytochemistry (ICC), immunohistochemistry (IHC), and Western blot (WB) applications.